Last reviewed 2026-04-23 · How we verify

Ocrelizumab SC

Ocrelizumab SC is a monoclonal antibody that targets CD20 on B cells.

Ocrelizumab SC is a monoclonal antibody that targets CD20 on B cells. Used for Relapsing forms of multiple sclerosis, Primary progressive multiple sclerosis, Non-Hodgkin's lymphoma.

At a glance

Mechanism of action

By binding to CD20, ocrelizumab SC induces direct and indirect mechanisms of action that lead to the depletion of B cells, which play a key role in the pathogenesis of multiple sclerosis and non-Hodgkin's lymphoma.

Approved indications

• Relapsing forms of multiple sclerosis
• Primary progressive multiple sclerosis
• Non-Hodgkin's lymphoma

Common side effects

• Infusion-related reactions
• Infections
• Neutropenia
• Thrombocytopenia
• Anemia

Key clinical trials

• A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
• An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment (PHASE3)
• A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) (PHASE2)
• Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (NA)
• Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation
• A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (PHASE3)
• A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis (PHASE1)
• Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.